Abstract | BACKGROUND: STUDY DESIGN: Randomized controlled trial. SETTING & PARTICIPANTS: INTERVENTION: OUTCOMES & MEASUREMENTS: The primary end point was kidney survival, defined as a 50% increase in baseline serum creatinine level. RESULTS: After follow-up for up to 48 months, 7 patients in the ACE-inhibitor group (24.1%) reached the primary end point compared with 1 patient (3%) in the combination group. Kaplan-Meier kidney survival was significantly better in the combination group than the ACE-inhibitor group after 24 and 36 months (96.6% versus 75.7%, 96.6% versus 66.2%; P = 0.001). Urine protein excretion significantly decreased in patients in the combination group compared with the ACE-inhibitor group (time-average proteinuria, 1.04 +/- 0.54 versus 1.57 +/- 0.86 g/d of protein; P = 0.01). Multivariate analysis showed that combination treatment (hazard ratio, 0.1; 95% confidence interval, 0.014 to 0.946) and time-average proteinuria (hazard ratio, 14.3; 95% confidence interval, 2.86 to 71.92) were independent predictors of kidney survival. LIMITATIONS: Small sample size, a single center, and slight imbalances at baseline. CONCLUSIONS: Our results suggest that the addition of steroid to ACE-inhibitor therapy provided additional benefit compared with an ACE inhibitor alone. However, this was a pilot study with a small number of participants achieving the end points, and thus further validation is necessary.
|
Authors | Jicheng Lv, Hong Zhang, Yuqing Chen, Guangtao Li, Lei Jiang, Ajay K Singh, Haiyan Wang |
Journal | American journal of kidney diseases : the official journal of the National Kidney Foundation
(Am J Kidney Dis)
Vol. 53
Issue 1
Pg. 26-32
(Jan 2009)
ISSN: 1523-6838 [Electronic] United States |
PMID | 18930568
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenal Cortex Hormones
- Angiotensin-Converting Enzyme Inhibitors
- Cilazapril
- Creatinine
- Prednisone
|
Topics |
- Adrenal Cortex Hormones
(adverse effects, therapeutic use)
- Adult
- Angiotensin-Converting Enzyme Inhibitors
(adverse effects, therapeutic use)
- Biopsy
- Cilazapril
(adverse effects, therapeutic use)
- Creatinine
(blood)
- Drug Therapy, Combination
- Female
- Glomerulonephritis, IGA
(blood, drug therapy, physiopathology)
- Humans
- Kidney
(pathology, physiopathology)
- Male
- Multivariate Analysis
- Outcome Assessment, Health Care
- Pilot Projects
- Prednisone
(adverse effects, therapeutic use)
- Proteinuria
(blood, drug therapy, physiopathology)
- Treatment Outcome
|